3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
35
Lung Neoplasms
7
Small Cell Lung Carcinoma
2
Resectable Non-small Cell Lung Cancer
2
Neoplasms
2
Squamous-Cell Lung Cancer
1
Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Nonsquamous Non-small Cell Lung Cancer
1
Non-Squamous Non-Small Cell Lung Cancer
1
Neoplasm Metastasis
1
NSCLC
1
Melanoma
1
Lymphatic Metastasis
1
Esophageal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Bronchogenic
1
Carcinoma
1
Bronchial Neoplasms
1
Advanced Non-small Cell Lung Cancer
1
Advanced Non Small Cell Lung Cancer
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
2
toripalimab
1
sintilimab
1
pemigatinib
1
osimertinib
1
durvalumab
1
Vinorelbine
1
Platinum Compounds
1
Nivolumab
1
Ipilimumab
1
Drug Therapy
1
AZD 6244
1
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Non Small Cell Lung Cancer
×
Platinum Compounds
×
Thoracic
×
Clear all
NCT04144608
2024-08-09
TOGATHER
Hunan Province Tumor Hospital
Phase 2
Completed
40 enrolled